+++
abstract = """The pharmaceutical industry is faced with steadily declining R&D efficiency which results in fewer drugs reaching the market despite increased investment. A major cause for this low efficiency is the failure of drug candidates in late-stage development owing to safety issues or previously undiscovered side-effects. We analyzed to what extent gene expression data can help to de-risk drug development in early phases by detecting the biological effects of compounds across disease areas, targets and scaffolds. For eight drug discovery projects within a global pharmaceutical company, gene expression data were informative and able to support go/no-go decisions. Our studies show that gene expression profiling can detect adverse effects of compounds, and is a valuable tool in early-stage drug discovery decision making."""
authors = ["Verbist B", "Klambauer G", "Vervoort L", "Talloen W", "Shkedy Z", "Thas O", "Bender A", "GÃ¶hlmann HWH", "Hochreiter S"]
date = 2015-05-01
doi = "10.1016/j.drudis.2014.12.014"
featured = false
highlight = true
math = true
publication = "*Drug Discovery Today* 2015; 20(5):505-513"
publication_short = "*Drug Discov Today* 2015; 20:505-13"
publication_types = ["2"]
summary = "*Drug Discovery Today* 2015; 20(5):505-513"
tags = ["Bigirumurame"]
title = "Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project"
+++
